BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32041153)

  • 1. Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.
    Ostano P; Mello-Grand M; Sesia D; Gregnanin I; Peraldo-Neia C; Guana F; Jachetti E; Farsetti A; Chiorino G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 3. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
    Tiwari R; Manzar N; Bhatia V; Yadav A; Nengroo MA; Datta D; Carskadon S; Gupta N; Sigouros M; Khani F; Poutanen M; Zoubeidi A; Beltran H; Palanisamy N; Ateeq B
    Nat Commun; 2020 Jan; 11(1):384. PubMed ID: 31959826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
    Zhao SG; Sperger JM; Schehr JL; McKay RR; Emamekhoo H; Singh A; Schultz ZD; Bade RM; Stahlfeld CN; Gilsdorf CS; Hernandez CI; Wolfe SK; Mayberry RD; Krause HM; Bootsma M; Helzer KT; Rydzewski N; Bakhtiar H; Shi Y; Blitzer G; Kyriakopoulos CE; Kosoff D; Wei XX; Floberg J; Sethakorn N; Sharifi M; Harari PM; Huang W; Beltran H; Choueiri TK; Scher HI; Rathkopf DE; Halabi S; Armstrong AJ; Beebe DJ; Yu M; Sundling KE; Taplin ME; Lang JM
    J Clin Invest; 2022 Nov; 132(21):. PubMed ID: 36317634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy considerations in neuroendocrine prostate cancer: what next?
    Beltran H; Demichelis F
    Endocr Relat Cancer; 2021 Jul; 28(8):T67-T78. PubMed ID: 34111024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
    Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
    Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study.
    Franko A; Berti L; Guirguis A; Hennenlotter J; Wagner R; Scharpf MO; de Angelis MH; Wißmiller K; Lickert H; Stenzl A; Birkenfeld AL; Peter A; Häring HU; Lutz SZ; Heni M
    Genes (Basel); 2020 Oct; 11(10):. PubMed ID: 33036464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated review on analysis of long non-coding RNAs as emerging diagnostic and therapeutic targets in prostate cancers.
    Ke Z; Hu X; Liu Y; Shen D; Khan MI; Xiao J
    Crit Rev Oncol Hematol; 2024 Apr; 196():104275. PubMed ID: 38302050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review.
    Abufaraj M; Ramadan R; Alkhatib A
    Curr Oncol; 2024 Mar; 31(3):1618-1632. PubMed ID: 38534956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.
    Wang Y; Xue H; Zhu X; Lin D; Dong X; Chen Z; Chen J; Shi M; Ni Y; Cao J; Wu R; Kang N; Pang X; Crea F; Lin YY; Collins CC; Gleave ME; Parolia A; Chinnaiyan A; Ong CJ; Wang Y
    bioRxiv; 2024 Apr; ():. PubMed ID: 38746377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
    Tsubonuma Y; Funakoshi K; Takaba T; Jyojima K; Minato A; Tomisaki I; Harada K; Fujimoto N
    J UOEH; 2024; 46(1):23-28. PubMed ID: 38479871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.
    Rao SR; Protheroe A; Cerundolo L; Maldonado-Perez D; Browning L; Lamb AD; Bryant RJ; Mills IG; Woodcock DJ; Hamdy FC; Tomlinson IPM; Verrill C
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting molecular, pathological, and clinical features associated with tumor neural/neuroendocrine heterogeneity.
    Cai L; DeBerardinis RJ; Xiao G; Minna JD; Xie Y
    iScience; 2023 Jun; 26(6):106983. PubMed ID: 37378310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of Cellular Plasticity in Prostate Cancer Progression.
    Tiwari R; Manzar N; Ateeq B
    Front Mol Biosci; 2020; 7():130. PubMed ID: 32754615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Reprogramming by Malat1 Depletion in Prostate Cancer.
    Nanni S; Aiello A; Salis C; Re A; Cencioni C; Bacci L; Pierconti F; Pinto F; Ripoli C; Ostano P; Baroni S; Lazzarino G; Tavazzi B; Pugliese D; Bassi P; Grassi C; Panunzi S; Chiorino G; Pontecorvi A; Gaetano C; Farsetti A
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Feb; 11(1):1095. PubMed ID: 32094369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer.
    Ku A; Fredsøe J; Sørensen KD; Borre M; Evander M; Laurell T; Lilja H; Ceder Y
    Front Oncol; 2021; 11():631021. PubMed ID: 33842337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of Prostate Cancer.
    Salamini-Montemurri M; Vizoso-Vázquez Á; Barreiro-Alonso A; Lorenzo-Catoira L; Rodríguez-Belmonte E; Cerdán ME; Lamas-Maceiras M
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review.
    Kouroukli O; Bravou V; Giannitsas K; Tzelepi V
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.